to market or make other penetration with T? Are we still burdoned with sharing revenue that deliverable?
If not, no matter what the market SHARE used to be vis a vis duo therapy, the SINGULAR market share will increase for ELN, if not and we are still liable for sharing profit based on BIIB contribution, the loss of market due to loss of DISTRIBUTION is going to drag us down.
We need a positive from those neuros that belies analyst drivel.
Where are we with this part of the equation-- still tied to BIIB, or are we on our own now?